How GxP Influences Label Claims, Safety Text and Risk Management Content Understanding the Integration of GxP and Regulatory Affairs in Pharma Context Regulatory Affairs (RA) encompasses a critical framework within the pharmaceutical sector, guiding product development from conception through marketing authorization, emphasizing compliance with established GxP (Good Practice) principles. The intricate relationship among various GxP quality systems—GMP (Good Manufacturing Practice), GCP (Good Clinical Practice), GLP (Good Laboratory Practice), GVP (Good Vigilance Practice), and GDP (Good Distribution Practice)—significantly influences regulatory submissions, including label claims, safety text, and risk management content. Ensuring conformity with both GxP principles and regulatory expectations is essential…

Case Studies: GxP Failures That Became Regulatory Crises Case Studies: GxP Failures That Became Regulatory Crises The pharmaceutical landscape is heavily regulated, with strict guidelines governing various aspects of product development, manufacturing, and post-market surveillance. Among these guidelines, Good Practice (GxP) standards are paramount for ensuring compliance and product integrity. This article explores the integration of GxP quality systems with regulatory affairs, focusing on case studies where failures in pharmacovigilance and other GxP areas resulted in severe regulatory repercussions. It aims to provide insights for Regulatory Affairs, Chemistry, Manufacturing and Controls (CMC), and Labelling teams across the US, EU, and…

Designing GxP Governance Committees with RA at the Table Designing GxP Governance Committees with RA at the Table In the highly regulated pharmaceutical and biotech industries, the integration of Good Practice (GxP) governance structures with Regulatory Affairs (RA) is imperative for ensuring compliance and effective risk management. This article aims to provide a deep and structured explanation of the relevant regulations, guidelines, and expectations that outline the interaction between GxP quality systems and regulatory frameworks across the US, UK, and EU. Context The GxP framework encompasses various practices—Good Manufacturing Practice (GMP), Good Clinical Practice (GCP), Good Laboratory Practice (GLP), Good…

GxP in Virtual, Outsourced and Platform-Based Pharma Models GxP in Virtual, Outsourced and Platform-Based Pharma Models The evolution of pharmaceutical development has resulted in a significant shift towards virtual, outsourced, and platform-based business models. In this landscape, maintaining robust Good Practice (GxP) quality systems is critical for regulatory compliance and product integrity. This article aims to provide a comprehensive overview of GxP integration into Regulatory Affairs (RA) practices within this context, specifically focusing on the implications for pharmacovigilance, particularly within the framework of IQVIA pharmacovigilance. Context GxP encompasses a set of quality guidelines and regulations that govern the development, manufacturing,…

Digitalisation, Data Integrity and the Next Generation of GxP Digitalisation, Data Integrity and the Next Generation of GxP Context In the rapidly evolving pharmaceutical landscape, integrating digitalisation and ensuring data integrity has become pivotal for maintaining compliance with Good Practice (GxP) regulations. Regulatory Affairs (RA) professionals play a crucial role in ensuring that pharmaceutical products meet stringent quality standards through effective oversight of processes that include Good Manufacturing Practice (GMP), Good Clinical Practice (GCP), Good Laboratory Practice (GLP), Good Pharmacovigilance Practice (GVP), and Good Distribution Practice (GDP). This article serves as a comprehensive manual for Regulatory Affairs, highlighting the interconnectedness…

Risk-Based Thinking: Prioritising GxP Controls That Matter Most Risk-Based Thinking: Prioritising GxP Controls That Matter Most The integration of Good Automated Manufacturing Practice (GxP) quality systems with regulatory affairs is critical within the pharmaceutical sector, especially concerning pharmacovigilance systems. The regulatory landscape across the US, UK, and EU emphasizes adherence to quality standards, ensuring patient safety while maintaining compliance. This article aims to provide a comprehensive overview of risk-based thinking and communication within GxP contexts, with a spotlight on pharmacovigilance systems. Regulatory Affairs Context In regulatory affairs, the focus is primarily on ensuring that pharmaceutical products are developed, manufactured, and…

Metrics and Dashboards That Reflect True GxP Health Metrics and Dashboards That Reflect True GxP Health In today’s complex pharmaceutical landscape, the integration of Good Practice (GxP) quality systems with regulatory affairs is crucial for ensuring compliance and promoting the successful development and commercialization of drugs. Effective metrics and dashboards are essential tools for regulatory compliance consulting teams, allowing them to assess the health of GxP practices such as Good Manufacturing Practice (GMP), Good Clinical Practice (GCP), Good Laboratory Practice (GLP), Good Pharmacovigilance Practice (GVP), and Good Distribution Practice (GDP). This article serves as a comprehensive manual for Regulatory Affairs…

Aligning Vendor and Partner GxP Standards with Sponsor Expectations Aligning Vendor and Partner GxP Standards with Sponsor Expectations In the highly regulated pharmaceutical and biotechnology sectors, ensuring that vendors and partners adhere to Good Practice (GxP) standards is crucial for safeguarding product quality, safety, and efficacy. This article provides a comprehensive regulatory explainer manual concerning GxP quality systems, focusing specifically on the integration of these standards with sponsor expectations. It encompasses critical regulations, guidelines, and practical tips for the Regulatory Affairs (RA) professionals involved in compliance, quality assurance, and contract management. Context GxP refers to a set of regulations and…

GxP Readiness for Accelerated and Innovative Regulatory Pathways GxP Readiness for Accelerated and Innovative Regulatory Pathways Context The regulatory landscape for pharmaceuticals is constantly evolving, with a particular emphasis on accelerating the development timelines of therapies, especially in response to public health emergencies. Regulatory authorities such as the FDA (United States), EMA (European Union), and MHRA (United Kingdom) are implementing innovative pathways to facilitate quicker access to life-saving medications and therapies. As regulatory affairs (RA) professionals, it is imperative to have a robust understanding of Good Practice (GxP) principles to ensure compliance throughout the drug development life cycle. GxP encompasses…

Internal Communications That Keep GxP Top-of-Mind Across Functions Internal Communications That Keep GxP Top-of-Mind Across Functions In the complex landscape of pharmaceutical development and regulation, effective communication across functions is crucial to maintaining compliance with Good Practices (GxP) standards. This article delves into the importance of integrating GxP quality systems within Regulatory Affairs (RA) and offers insight into best practices for ensuring that GxP remains a priority across various departmental functions, particularly in light of the increasing emphasis on regulatory compliance in markets like the US, EU, and UK. Context Regulatory Affairs plays a pivotal role in ensuring that pharmaceutical…